MedTrace Logo

Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)

NCT01349920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2018-10-15

Study results available
· View outcomes & findings →

Summary

This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.

Conditions

  • Crohn Disease

Interventions

DRUG

Infliximab

Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-28
Primary Completion
2015-09-28
Completion
2015-09-28

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01349920 on ClinicalTrials.gov